No connection

Search Results

KYNB vs MLSS

KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%
MLSS
Milestone Scientific Inc.
BEARISH
Price
$0.31
Market Cap
$27.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KYNB
--
MLSS
--
Forward P/E
KYNB
-0.7
MLSS
-7.75
P/B Ratio
KYNB
-0.97
MLSS
8.86
P/S Ratio
KYNB
4.51
MLSS
3.05
EV/EBITDA
KYNB
0.13
MLSS
-4.42

Profitability

Gross Margin
KYNB
-273.8%
MLSS
71.4%
Operating Margin
KYNB
-1058.65%
MLSS
-52.46%
Profit Margin
KYNB
2848.63%
MLSS
-63.77%
ROE
KYNB
--
MLSS
-132.38%
ROA
KYNB
-16.96%
MLSS
-40.45%

Growth

Revenue Growth
KYNB
-59.3%
MLSS
2.2%
Earnings Growth
KYNB
--
MLSS
--

Financial Health

Debt/Equity
KYNB
4.37
MLSS
0.36
Current Ratio
KYNB
3.39
MLSS
1.81
Quick Ratio
KYNB
3.19
MLSS
0.44

Dividends

Dividend Yield
KYNB
--
MLSS
--
Payout Ratio
KYNB
0.0%
MLSS
0.0%

AI Verdict

KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)
MLSS BEARISH

MLSS exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from chronic unprofitability with a profit margin of -63.77% and an ROE of -132.38%, while revenue growth has stagnated at a negligible 2.20% YoY. Despite a low debt-to-equity ratio, the poor quick ratio (0.44) and consistent earnings misses over 25 quarters suggest a failing business model. The stock is technically bearish with a 5-year price decline of 87.7%, making it a high-risk speculative asset with no fundamental floor.

Strengths
Strong gross margin of 71.40% suggesting a viable product core
Low Debt/Equity ratio (0.36) indicating minimal long-term leverage
Current ratio of 1.81 provides a temporary liquidity buffer
Risks
Critical financial health (Piotroski F-Score 1/9)
Chronic net losses with negative profit and operating margins
Stagnant revenue growth (2.20%) failing to scale the business

Compare Another Pair

KYNB vs MLSS: Head-to-Head Comparison

This page compares Kyntra Bio, Inc. (KYNB) and Milestone Scientific Inc. (MLSS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile